Blueprint Medicines Corp To Discuss The Registrational PIONEER Trial Data Of AYVAKIT In Indolent SM Call Transcript
Thank you all for joining. I would like to welcome you all to this morning's Blueprint Medicines Conference Call. My name is Brika, and I'll be your operator for today's call. (Operator Instructions)
I would now like to turn the call over to Jenna Cohen. You may begin.
Thank you, Brika. Good morning, everyone, and welcome to Blueprint Medicines conference call to discuss the presentation of our detailed AYVAKIT data in patients with indolent systemic mastocytosis. Yesterday afternoon, we issued a press release, which outlines the topics we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.
Joining me on today's call are Kate Haviland, Chief Executive Officer; Dr. Becker Hewes, Chief Medical Officer; and Dr. Mariana Castells, Director of the Mastocytosis
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |